Prevention of Cardiotoxicity in the Cancer Patient

Wenners Ballard; Justin Vader

doi:10.1007/s12170-017-0558-1

Prevention of Cardiotoxicity in the Cancer Patient

Wenners Ballard
, Justin Vader

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Purpose of Review: This review discusses the current understanding of cardiotoxicities and prevention strategies for several agents including anthracyclines, HER2 monoclonal antibodies, tyrosine kinase inhibitors, and fluoropyrimidines. Recent Findings: Heart disease and cancer are by far the most common causes of death in the USA and may coincide in a given individual. Life-prolonging therapies for heart disease and cancer continue to evolve, with a particular proliferation of new agents to treat cancer. These advances in the treatment of cancer have led to an expanding population of cancer survivors. Due to the natural coincidence of heart disease and cancer and due to the cardiotoxicities of certain chemotherapies, it is increasingly important for cardiologists and oncologists to understand and anticipate cardiovascular events in the setting of cancer treatment. Summary: A growing body of literature on the incidence of, prediction of, and prevention of cardiotoxicity in the cancer patient is now available.

Original language	English
Article number	31
Journal	Current Cardiovascular Risk Reports
Volume	11
Issue number	11
DOIs	https://doi.org/10.1007/s12170-017-0558-1
State	Published - Nov 1 2017

Keywords

Anthracyclines
Cardiotoxicity
Cardiotoxicity and cancer patients
Left ventricular ejection fraction (LVEF)

Access to Document

10.1007/s12170-017-0558-1

Cite this

@article{b1414990666c466ba888755c4264719a,

title = "Prevention of Cardiotoxicity in the Cancer Patient",

abstract = "Purpose of Review: This review discusses the current understanding of cardiotoxicities and prevention strategies for several agents including anthracyclines, HER2 monoclonal antibodies, tyrosine kinase inhibitors, and fluoropyrimidines. Recent Findings: Heart disease and cancer are by far the most common causes of death in the USA and may coincide in a given individual. Life-prolonging therapies for heart disease and cancer continue to evolve, with a particular proliferation of new agents to treat cancer. These advances in the treatment of cancer have led to an expanding population of cancer survivors. Due to the natural coincidence of heart disease and cancer and due to the cardiotoxicities of certain chemotherapies, it is increasingly important for cardiologists and oncologists to understand and anticipate cardiovascular events in the setting of cancer treatment. Summary: A growing body of literature on the incidence of, prediction of, and prevention of cardiotoxicity in the cancer patient is now available.",

keywords = "Anthracyclines, Cardiotoxicity, Cardiotoxicity and cancer patients, Left ventricular ejection fraction (LVEF)",

author = "Wenners Ballard and Justin Vader",

note = "Publisher Copyright: {\textcopyright} 2017, Springer Science+Business Media, LLC.",

year = "2017",

month = nov,

day = "1",

doi = "10.1007/s12170-017-0558-1",

language = "English",

volume = "11",

journal = "Current Cardiovascular Risk Reports",

issn = "1932-9520",

number = "11",

}

TY - JOUR

T1 - Prevention of Cardiotoxicity in the Cancer Patient

AU - Ballard, Wenners

AU - Vader, Justin

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Purpose of Review: This review discusses the current understanding of cardiotoxicities and prevention strategies for several agents including anthracyclines, HER2 monoclonal antibodies, tyrosine kinase inhibitors, and fluoropyrimidines. Recent Findings: Heart disease and cancer are by far the most common causes of death in the USA and may coincide in a given individual. Life-prolonging therapies for heart disease and cancer continue to evolve, with a particular proliferation of new agents to treat cancer. These advances in the treatment of cancer have led to an expanding population of cancer survivors. Due to the natural coincidence of heart disease and cancer and due to the cardiotoxicities of certain chemotherapies, it is increasingly important for cardiologists and oncologists to understand and anticipate cardiovascular events in the setting of cancer treatment. Summary: A growing body of literature on the incidence of, prediction of, and prevention of cardiotoxicity in the cancer patient is now available.

AB - Purpose of Review: This review discusses the current understanding of cardiotoxicities and prevention strategies for several agents including anthracyclines, HER2 monoclonal antibodies, tyrosine kinase inhibitors, and fluoropyrimidines. Recent Findings: Heart disease and cancer are by far the most common causes of death in the USA and may coincide in a given individual. Life-prolonging therapies for heart disease and cancer continue to evolve, with a particular proliferation of new agents to treat cancer. These advances in the treatment of cancer have led to an expanding population of cancer survivors. Due to the natural coincidence of heart disease and cancer and due to the cardiotoxicities of certain chemotherapies, it is increasingly important for cardiologists and oncologists to understand and anticipate cardiovascular events in the setting of cancer treatment. Summary: A growing body of literature on the incidence of, prediction of, and prevention of cardiotoxicity in the cancer patient is now available.

KW - Anthracyclines

KW - Cardiotoxicity

KW - Cardiotoxicity and cancer patients

KW - Left ventricular ejection fraction (LVEF)

UR - https://www.scopus.com/pages/publications/85029164394

U2 - 10.1007/s12170-017-0558-1

DO - 10.1007/s12170-017-0558-1

M3 - Review article

AN - SCOPUS:85029164394

SN - 1932-9520

VL - 11

JO - Current Cardiovascular Risk Reports

JF - Current Cardiovascular Risk Reports

IS - 11

M1 - 31

ER -

Prevention of Cardiotoxicity in the Cancer Patient

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this